Antares Pharma (ATRS) Misses Q4 EPS by 3c

Antares Pharma (NASDAQ: ATRS) reported Q4 EPS of ($0.08), $0.03 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $8.4 million versus the consensus estimate of $8.5 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• Cerebras Q1 EPS miss sends shares down 9% after-hours